NCT05503550No Longer Available不适用
Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
研究设计
- 研究类型
- Expanded Access
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Unknown
不适用
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05757973Janssen Research & Development, LLC
Available
不适用
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Metastatic Castration-Resistant Prostate CancerNCT05650476Pfizer
Unknown
不适用
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)Depressive Disorder, Treatment-ResistantNCT03829579Janssen Research & Development, LLC
No Longer Available
不适用
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)Multiple MyelomaNCT05238311Pfizer
Approved For Marketing
不适用
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) DaratumumabNCT04264884Janssen Research & Development, LLC